The European Commission's much-awaited guideline on good manufacturing practices (GMP) for advanced therapy medicinal products (ATMPs) is likely to be published in the first half of 2017 as a stand-alone document. The document has been in the making for over a year and has undergone two rounds of stakeholder consultation.
Initial concerns that the industry had regarding the format of the final document – i.e
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?